DUSP1 and non-small cell lung carcinoma: Knockdown YAP1 combined with osimertinib can transcriptional induce DUSP1, proceed to dephosphorylated EGFR/MAPK signaling and phosphorylate YAP1 to modulating the osimertinib resistance of NSCLC.